Delivery Order SPE2DB22D2009-SPE2DB25FL9JZ
- Not listed
- The Defense Logistics Agency awarded a $1,619.52 delivery order to AmerisourceBergen Drug Corp on June 3, 2025, for the supply of HAVRIX 720 Unit/0.5 ML syringes. This firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility, with an...
- The Defense Logistics Agency (DLA) awarded a $1,417.08 delivery order to AmerisourceBergen Drug Corp for HAVRIX 720 Unit/0.5 ML syringes, with an ultimate completion date of July 14, 2025. This firm fixed-price contract, awarded on July 11, 2025, is non-set-aside and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,490.36 to AmerisourceBergen Drug Corp for the supply of HAVRIX 1,440 Unit/ML vaccine syringes. This competitively awarded, firm fixed-price delivery order was issued on August 7, 2025, with an ultimate completion date of August 8, 2025. The contract specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,597.88 to AmerisourceBergen Drug Corp for 1,440 units/mL of Havrix vaccine in syringes. The contract, awarded on August 15, 2025, with an ultimate completion date of August 18, 2025, utilizes a firm fixed price structure with no set-aside designation. Performance will be conducted at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of HAVRIX 1,440 Unit/ML Syringe vaccines valued at $1,339.10. This is a firm fixed-price delivery order with no set-aside designation, indicating the award resulted from open competition. The order is scheduled for completion by August 7, 2025, with performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 16, 2025, for 1,440 units of Havrix 1-unit/mL vaccine syringes, valued at $6,200.90 under a firm fixed-price contract type. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999.99 billion through December 2026. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $2,420.70 to AmerisourceBergen Drug Corp for the supply of Havrix 1,440 Unit/mL syringes. The contract, which was competitively awarded with no set-aside designation, carries an ultimate completion date of September 3, 2025, just one day after the award date of September 2, 2025. This delivery order operates under a firm fixed price arrangement and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $8,097.60 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Havrix 720 Unit/0.5 mL syringes. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by August 12, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $12,136.36 for 1,440 units/mL of HAVRIX vaccine syringes on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a single transaction under the company's larger pharmaceutical supply relationship...
- The Defense Logistics Agency awarded a $4,048.80 delivery order to AmerisourceBergen Drug Corp for Havrix 720 Unit/0.5 ML syringes on September 11, 2025, with an ultimate completion date of September 12, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The vaccine product will be...
- SPE2DB22D2009Indefinite Delivery Contract
- SPE2DB22D2009-SPE2DB25FL9JZDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,828.20 to AmerisourceBergen Drug Corp for HAVRIX 720 Unit/0.5 ML syringes. The contract is a firm fixed price delivery order with no set-aside designation, awarded on May 27, 2025, with an ultimate completion date of May 28, 2025. Performance will take place at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement through its comprehensive IDC vehicle that enables supply of pharmaceutical products and medical commodities to support military healthcare programs worldwide. The company's federal contract portfolio demonstrates extensive experience fulfilling diverse medical supply needs for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This specific delivery order for HAVRIX vaccine syringes supports the company's role as a key supplier within DLA's global pharmaceutical support framework, which is transitioning toward the Pharmaceutical Prime Vendor Global Program Generation V with potential multiple regional awards.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 5/27/25 |